Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura Street 4, 50-367 Wroclaw, Poland.
Department of Drugs Form Technology, Wroclaw Medical University, Borowska Street 211A, 50-556 Wroclaw, Poland.
Viruses. 2021 Mar 8;13(3):436. doi: 10.3390/v13030436.
The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48-72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group ( = 0.03460). The plasma-treated group also showed a significantly milder course of infection ( = 0.03807), characterized by less severe symptoms and faster recovery ( = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies.
恢复期血浆在 COVID-19 治疗中的应用可能导致感染过程更轻微，并与改善结局相关。确定高危人群的最佳治疗方法至关重要，例如血液系统恶性肿瘤患者。我们分析了一组 23 例血液系统恶性肿瘤合并 COVID-19 的患者，这些患者在感染后 48-72 小时接受了血浆治疗，并与接受其他治疗的 22 例历史对照组进行了比较。接受恢复期血浆治疗的患者的总体生存率明显高于历史对照组（=0.03460）。血浆治疗组的感染过程也明显较轻（=0.03807），表现为症状较轻，恢复较快（=0.00001）。总之，我们已经证明，恢复期血浆是一种有效的治疗方法，其早期给药可改善血液系统恶性肿瘤合并 COVID-19 患者的临床状况，加快病毒清除速度，并延长总体生存率。据我们所知，这是第一份分析恢复期血浆在血液系统恶性肿瘤患者队列中的疗效的报告。
